Exercise capacity as measured by the exercise endurance test at day 2, week 6 and week 12 (intent-to-treat population including data collected following discontinuation from study treatment)
| Placebo | UMEC/VI | p-value | |
| Subjects | n=198 | n=198 | |
| Week 12 (primary end-point) | n=157 | n=172 | |
| Least squares change from baseline | −5.4±9.68 | −2.1±9.29 | |
| Difference from placebo (95% CI) | 3.3 (−21.1–27.7) | 0.790 | |
| Day 2 | n=178 | n=185 | |
| Least squares change from baseline | 5.1±7.79 | 32.3±7.62 | |
| Difference from placebo (95% CI) | 27.2 (8.2–46.2) | 0.005 | |
| Week 6 | n=167 | n=179 | |
| Least squares change from baseline | −5.6±9.63 | 22.0±9.29 | |
| Difference from placebo (95% CI) | 27.6 (3.3–52.0) | 0.026 |
Data are presented as mean±se, unless otherwise stated. UMEC/VI: umeclidinium/vilanterol.